Duration of allergen immunotherapy in respiratory allergy: When is enough, enough?

Annals of Allergy, Asthma and Immunology

Volumn 98, Issue 5, 2007, Pages 416-426

  Cox, Linda ^a   Cohn, John R ^b  

^a Allergy and Asthma Center   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ALLPYRAL; BEE VENOM; GRASS POLLEN EXTRACT; RAGWEED ANTIGEN; VENOM;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HUMAN; HYPOTENSION; IMMUNOTHERAPY; MEDLINE; PRIORITY JOURNAL; RELAPSE; RESPIRATORY TRACT ALLERGY; REVIEW; RHINOCONJUNCTIVITIS; URTICARIA;

EID: 34248585196     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60755-7     Document Type: Review

References (42)

1. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109:251-256.
2. Polosa R, Al-Delaimy WK, Russo C, Piccillo G, Sarva M. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res. 2005;6:153.
3. Polosa R, Li Gotti F, Mangano G, et al. Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy. 2004;59:1224-1228.
4. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114:851-857.
5. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract, VI: specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol. 1997;99:450-453.
6. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy: a six-year follow-up study. Clin Exp Allergy. 2001;31:1392-1397.
7. Purello-D'Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not: a retrospective study. Clin Exp Allergy. 2001;31:1295-1302.
8. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy. 2004;59:1205-1210.
9. Bernstein JA. Pharmacoeconomic considerations for allergen immunotherapy. Clin Allergy Immunol. 2004;18:151-164.
10. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354:1985-1997.
11. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054-1063.
12. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol. 2006;117:169-175.
13. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol. 2004;113:1129-1136.
14. Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol. 1993;91:734-737.
15. Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol. 2004;114:869-886.
16. Golden DBK, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol. 2000;105:385-390.
17. Golden DBK, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM. Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol. 1998;101:298-302.
18. van Halteren HK, van der Linden PW, Burgers JA, Bartelink AK. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge. J Allergy Clin Immunol. 1997;100(6 pt 1):767-70.
19. Lerch E, Müller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol. 1998;101:606-612.
20. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341:468-475.
21. Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract, V: duration of the efficacy of immunotherapy after its cessation. Allergy. 1996;51:430-433.
22. Hedlin G, Heilborn H, Lilja G, et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol. 1995;96(6 pt 1):879-85.
23. Ebner C, Kraft D, Ebner H. Booster immunotherapy (BIT). Allergy. 1994;49:38-42.
24. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy. 2002;57:306-312.
25. Eng PA, Borer-Reinhold M, Heijnen IAFM, Gnehm HPE. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy. 2006;61:198-201.
26. Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? follow-up study in patients with grass pollen rhinitis. Allergy. 1988;43:523-529.
27. Jacobsen L, Nuchel Petersen B, Wihl IA, Lowenstein H, Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts, IV: results from long-term (6-year) follow-up. Allergy. 1997;52:914-920.
28. Naclerio RM, Proud D, Moylan B, et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol. 1997;100:293-300.
29. Ewan PW, Deighton J, Wilson AB, Lachmann PJ. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings. Clin Exp Allergy. 1993;23:647-660.
30. Djurup R, Malling HJ. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy. 1987;17:459-468.
31. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004;113:1025-1034; quiz 35.
32. Konno S, Golden DB, Schroeder J, Hamilton RG, Lichtenstein LM, Huang SK. Increased expression of osteopontin is associated with long-term bee venom immunotherapy. J Allergy Clin Immunol. 2005;115:1063-1067.
33. Golden DB, Marsh DG, Freidhoff LR, et al. Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol. 1997;100(6 pt 1):760-6.
34. Wilcock L, K FN, Paraskavopoulos G, Till SJ, SR, Durham SR. Induction of IL-10 occurs early and precedes serum IgG blocking activity during a cluster regimen of grass pollen immunotherapy [abstract]. J Allergy Clin Immunol. 2006;117:330.
35. Michils A, Baldassarre S, Ledent C, Mairesse M, Gossart B, Duchateau J. Early effect of ultrarush venom immunotherapy on the IgG antibody response. Allergy. 2000;55:455-462.
36. van Neerven RJ, Arvidsson M, Ipsen H, Sparholt SH, Rak S, Wurtzen PA. A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy. 2004;34:420-428.
37. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol. 2003;112:915-922.
38. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta; the role of T regulatory cells. Immunology. 2006;117:433-442.
39. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 2003;111:1255-1261.
40. Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger JW. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol. 1991;88(3 pt 1):339-48.
41. Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res. 1966;3:331-333.
42. Shekelle PG WS, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999;318:593-596.